We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

241 hedge funds and large institutions have $2.44B invested in Protagonist Therapeutics in 2024 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 91 increasing their positions, 76 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

20% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 76

1.32% more ownership

Funds ownership: 104.84% → 106.16% (+1.3%)

10% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 41

0% more funds holding

Funds holding: 240 → 241 (+1)

8% less call options, than puts

Call options by funds: $8.73M | Put options by funds: $9.52M

12% less capital invested

Capital invested by funds: $2.78B → $2.44B (-$337M)

Holders
241
Holders Change
+1
Holders Change %
+0.42%
% of All Funds
3.17%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.09%
New
45
Increased
91
Reduced
76
Closed
41
Calls
$8.73M
Puts
$9.52M
Net Calls
-$795K
Net Calls Change
+$1.92M

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$43.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$39.7M
3
American Century Companies
American Century Companies
Missouri
+$15.4M
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$14.9M
5
Pictet Asset Management
Pictet Asset Management
Switzerland
+$12.6M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$54M
2
BlackRock
BlackRock
New York
-$14.8M
3
JFG
Jefferies Financial Group
New York
-$14.2M
4
Marshall Wace
Marshall Wace
United Kingdom
-$12.9M
5
CC
Checkpoint Capital
California
-$10.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$382M -$14.8M -339,678 -3%
FCM
2
Farallon Capital Management
California
$229M +$3.01M +69,000 +1%
RI
3
RTW Investments
New York
$212M +$3.16M +72,433 +1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$163M +$172K +3,956 +0.1%
State Street
5
State Street
Massachusetts
$129M +$6.43M +147,519 +5%
JJ
6
Johnson & Johnson
New Jersey
$94.5M – – –
BI
7
BVF Inc
California
$73.3M +$2.17M +49,848 +3%
Pacer Advisors
8
Pacer Advisors
Pennsylvania
$72.4M +$6.21M +142,376 +8%
JFG
9
Jefferies Financial Group
New York
$57.5M -$14.2M -325,201 -18%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$53.8M +$3.63M +83,185 +6%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$53.2M +$103K +2,366 +0.2%
PA
12
Perceptive Advisors
New York
$49.1M -$4.49M -102,901 -7%
ACM
13
ADAR1 Capital Management
Texas
$39.4M +$1.7M +39,038 +4%
DTC
14
Deep Track Capital
Connecticut
$38.6M +$43.6M +1,000,000 New
Wellington Management Group
15
Wellington Management Group
Massachusetts
$36.3M +$39.7M +909,998 +3,025%
American Century Companies
16
American Century Companies
Missouri
$35.8M +$15.4M +353,511 +62%
Goldman Sachs
17
Goldman Sachs
New York
$29.3M -$2.75M -63,166 -8%
Invesco
18
Invesco
Georgia
$28.5M +$3.74M +85,800 +13%
EP
19
Eversept Partners
New York
$26.2M +$10.2M +233,583 +52%
Northern Trust
20
Northern Trust
Illinois
$24.3M +$2.11M +48,491 +8%
WP
21
Woodline Partners
California
$22.5M +$5.05M +115,809 +25%
Charles Schwab
22
Charles Schwab
California
$22.3M +$563K +12,906 +2%
JP Morgan Chase
23
JP Morgan Chase
New York
$22.3M +$3.23M +73,992 +15%
Morgan Stanley
24
Morgan Stanley
New York
$20.9M -$3.85M -88,308 -14%
Fidelity Investments
25
Fidelity Investments
Massachusetts
$17.1M -$509K -11,680 -3%
1
2 3 4 5

PTGX Hedge Fund Activity: Q4 2024 in Review

241 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2024, worth a combined $2.44B — down 12% from $2.78B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new PTGX positions and 41 closed out — a net gain of 4 holders — while 91 added to existing stakes and 76 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $43.6M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $54M sold.

  • 241 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2024, up from 240 in Q3 2024.
  • Funds reported $2.44B of Protagonist Therapeutics stock for Q4 2024, down 12% quarter-over-quarter.
  • 45 funds opened new Protagonist Therapeutics positions in Q4 2024 and 41 closed out, a net change of +4 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2024 was Deep Track Capital, an estimated $43.6M added.
  • The largest Protagonist Therapeutics seller in Q4 2024 was Adage Capital Partners, an estimated $54M sold.

Based on aggregated 13F filings for Q4 2024.